1:13 PM
 | 
Nov 06, 2018
 |  BC Extra  |  Clinical News

Nektar shares fall on updated response data for NKTR-214 combo

Nektar Therapeutics (NASDAQ:NKTR) was off $3.92 (10%) to $36.08 on Tuesday as investors digested updated response data released in an abstract ahead of this week's SITC meeting from a Phase I/II trial of NKTR-214 plus anti-PD-1 mAb Opdivo nivolumab.

The update appeared to disappoint investors who had hoped to see the response rate rise in a larger cohort of patients and with longer follow-up. However, the updated data, which showed no change from a 50% objective response rate (ORR) among patients with melanoma reported at the...

Read the full 410 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >